While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

But Matt Phipps, a William Blair analyst, noted that significant weight loss is often tied to declining bone mineral ... GIPR is involved in insulin release and glycemic control. Rival drugs from Eli ...

The company, headquartered in the key swing state of Pennsylvania, has announced the creation of 330 jobs in a significant ...

The Danish drugmaker and rival Eli Lilly have together sued dozens of medical spas, weight-loss clinics, compounding ...